HHHRC offers buprenorphine (Suboxone®) induction at our Honolulu clinic. For questions, or to make an appointment, call us at (808) 521-2437.
For Medical Providers
For providers who wish to refer, please complete the Opioid Use Disorder referral form and/or call the clinic line.
Click the button below to download our buprenorphine instruction sheet with helpful information for starting Suboxone®.
WHAT IS BUPRENORPHINE? From the Substance Abuse and Mental Health Services Administration (SAMHSA)
Buprenorphine is used to treat Opioid Use Disorder (OUD). Approved for clinical use in October 2002 by the Food and Drug Administration (FDA), medications such as buprenorphine, in combination with counseling and behavioral therapies, provide a whole-patient approach to the treatment of opioid dependency. When taken as prescribed, buprenorphine is safe and effective.
As with all medications used in MAT, buprenorphine is prescribed as part of a comprehensive treatment plan that includes counseling and participation in social support programs. Buprenorphine offers several benefits to those with opioid dependency and to others for whom treatment in a methadone clinic is not preferred or is less convenient.
Buprenorphine has unique pharmacological properties that help:
Lower the potential for misuse
Diminish the effects of physical dependency to opioids, such as withdrawal symptoms and cravings
Increase safety in cases of overdose
Buprenorphine is an opioid partial agonist. This means that, like opioids, it produces effects such as euphoria or respiratory depression at low to moderate doses. With buprenorphine, however, these effects are weaker than full opioid agonists such as heroin and methadone. Buprenorphine’s opioid effects increase with each dose until at moderate doses they level off, even with further dose increases. This “ceiling effect” lowers the risk of misuse, dependency, and side effects. Also, because of buprenorphine’s long-acting agent, many patients may not have to take it every day.
Information about Buprenorphine from the Substance Abuse and Mental Health Services Administration (SAMHSA)
Medication to Treat Addiction Involving Opioid Use 2018 Fact Sheet from the American Society of Addiction Medicine (ASAM)
HHHRC RELEASES 2019 SYRINGE EXCHANGE ANNUAL REPORT
Hawai῾i Health & Harm Reduction Center released our latest annual report outlining the ongoing successes of Hawaiʿi’s publicly-funded statewide syringe access program (SEP), which began in 1989 to curb the spread of HIV/AIDS. Over 1.18 million syringes were exchanged during the report’s 2019 time frame.